Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada

Status

Enrolling by invitation

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06312189

Enrollment

Registered

2024-03-15

Start date

2024-04-24

Completion date

2028-04-01

Last updated

2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chorea, Huntington

Brief summary

This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.

Interventions

DRUGValbenazine

vesicular monoamine transporter 2 (VMAT2) inhibitor

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Participated in Study NBI-98854-HD3006 and completing dosing through the Week 156 visit; or were actively participating, receiving study treatment, and completed an early termination visit Study NBI-98854-HD3006 at the time of the study closure at sites in Canada. * Participants of childbearing potential must agree to use contraception consistently while participating in the study until 30 days after last dose of the study treatment. Key

Exclusion criteria

* Have difficulty swallowing * Are currently pregnant or breastfeeding * Have a medically significant abnormality, physical examination finding, clinically significant laboratory abnormality

Design outcomes

Primary

Measure	Time frame
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)	Up to Week 210

Countries

Canada

Contacts

STUDY_DIRECTORClinical Development Lead

Neurocrine Biosciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026